Saltar al contenido
Merck
Todas las fotos(1)

Documentos

SML3710

Sigma-Aldrich

Linaclotide

≥95% (HPLC)

Sinónimos:

CCEFCCNPACTGCF-OH cyclo(1-6),(2-10),(5-13)-tris(disulfide), Cys-Cys-Glu-Tyr-Cys-Cys-Asn-Pro-Ala-Cys-Thr-Gly-Cys-Tyr-OH cyclo(1-6),(2-10),(5-13)-tris(disulfide), L-Cysteinyl-L-cysteinyl-L-α-glutamyl-L-tyrosyl-L-cysteinyl-L-cysteinyl-L-asparaginyl-L-prolyl-L-alanyl-L-cysteinyl-L-threonylglycyl-L-cysteinyl-L-tyrosine-OH cyclo(1-6),(2-10),(5-13)-tris(disulfide)

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C59H79N15O21S6
Número de CAS:
851199-59-2
Peso molecular:
1526.74
UNSPSC Code:
12352200
NACRES:
NA.77

Quality Level

100

assay

≥95% (HPLC)

form

(Powder or Lyophilized powder or film)

storage condition

desiccated

color

white to off-white

storage temp.

-10 to -25°C

Biochem/physiol Actions

Linaclotide is an orally active guanylate cyclase-C (GC-C) agonist that competes against bacterial STa enterotoxin binding to intestinal mucosal membranes from wild-type, but not GC-C null, mice (Ki = 16.4 nM). Linaclotide stimulates fluid secretion, upregulates cGMP accumulation in the intestinal lumen (5 μg/100 μL via injection into surgically ligated intestinal loops), and significantly increases the rate of gastrointestinal transit when administered orally in mice in vivo (100 μg/kg p.o.).

Caution

Hygroscopic

pictograms

Exclamation mark
GHS07

signalword

Warning

hcodes

H302

Hazard Classifications

Acute Tox. 4 Oral

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Robert W Busby et al.
European journal of pharmacology, 649(1-3), 328-335 (2010-09-25)
Linaclotide is a first-in-class, orally administered 14-amino acid peptide that is in development for the treatment of irritable bowel syndrome with constipation and chronic constipation. We have characterized the solution structure of linaclotide, the in vitro binding and agonist activity
John Cuppoletti et al.
BMC pharmacology, 12, 3-3 (2012-05-05)
Linaclotide has been proposed as a treatment for the same gastrointestinal indications for which lubiprostone has been approved, chronic idiopathic constipation and irritable bowel syndrome with constipation. Stressors damage the epithelial cell barrier and cellular homeostasis leading to loss of
Alexander P Bryant et al.
Life sciences, 86(19-20), 760-765 (2010-03-24)
Linaclotide is an orally administered 14-amino acid peptide being developed for the treatment of constipation-predominant irritable bowel syndrome (IBS-C) and chronic constipation. We determined the stability of linaclotide in the intestine, measured the oral bioavailability, and investigated whether the pharmacodynamic

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico